In this way, it has been demonstrated that a short peptide, termed SP16, derived from serine-protease inhibitors (SERPINs), interacts with LRP1 and produces an agonist effect on the reduction of myocardial injury and preservation of cardiac systolic function in experimental acute myocardial infarction (AMI) [25,26]. Here, LRP1 is linked to myocardial infarction.